x

Publications

We bring together proven cell models and expertise in cardiovascular, neurological and immune cell biology. To keep building our expertise and infrastructure, our scientsts are continuously doing research to find new ways to differentiate, manufacture and charactarize iPSC-derived cell models for Drug Discovery and Cell Therapy. On this page, you will find our key publications.

Cardiovascular Safety

  • Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G, International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep

  • Spotlight Publication: Kopljar I, Lu H.R, Van Ammel K, Tekle F, Teisman A, Gallacher D.J. Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking. Stem Cell Reports.

  • Pugsley MK, Harter LH, de Korte T, Connaughton C, Authier S, Curtis J. Safety pharmacology methods and regulatory considerations evolve together. J Pharm Tox Meth
  • Bot CT, Juhasz K, Haeusermann F, Polonchuk L, Traebert M, Stoelzle-Feix S. Cross-site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes. J Pharm Tox Meth

  • Ncardia Conference Report. Mulder P, de Korte T, Dragicevic E, Kraushaar U, Printemps R, Vlaming MLH, Braam SR, and Valentin JP. Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report. J Pharmacol Toxicol Methods

  • Kopljar I, Hermans AN, Teisman A, Gallacher DJ, and Lu HR. Impact of calcium-sensitive dyes on the beating properties and pharmacological responses of human iPS-derived cardiomyocytes using the calcium transient assay. J Pharmacol Toxicol Methods

  • Koci B, Luerman G, Duenbostell A, Kettenhofen R, Bohlen H, Coyle L, Knight B, Ku W, Volberg W, Woska JR, Brown MP. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities. Toxicol Appl Pharmacol

  • Zhao L., Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep
  • Blinova K, Stohlman J, Vicente J, et al. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol Sci
  • Kopljar I, Gallacher DJ, De Bondt A, Cougnaud L, Vlaminckx E, Van den Wyngaert I, Lu HR. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells Transl Med

Drug Discovery

  • de Korte T, Katili PA, Mohd Yusof NAN, van Meer BJ, Saleem U, Burton FL, Smith GL, Clements P, Mummery CL, Eschenhagen T, Hansen A, Denning C, Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell-derived cardiomyocytes: fit for purpose or forever elusive? Annu Rev Pharmacol Toxicol.

  • Bruyneel AA, McKeithan WL, Feyen DA, Mercola M, Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease? Curr Opin Pharmacol

  • Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M, Opportunities in phenotypic drug discovery: an industry perspective. Nat Rev Drug Disc

  • Tang S, Xie M, Cao, N, Ding S, Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery. J Med Chem

  • Mullard A, Stem-cell discovery platforms yield first clinical candidates. Nat Rev Drug Discov

  • Vincent F, Loria P, Pregel M, Stanton R, Kitching L, Nocka K, Doyonnas R, Steppan C, Gilbert A, Schroeter T, Peakman MC, Developing predictive assays: the phenotypic screening "rule of 3". Sci Transl Med

Questions?

Would you like to receive more information?

We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.